The motivation for the review lies in the well-documented shortcomings of conventional diagnostic approaches. Microscopy, the historical mainstay, requires skilled microscopists, invasive sampling from lesions, bone marrow, lymph nodes or spleen, and it delivers sensitivity that falls sharply with parasite burden and operator experience. Serological tests, meanwhile, detect antibodies rather than the parasite itself, which means they cannot reliably distinguish active infection from past exposure, a critical limitation in endemic regions where a large share of the population may carry immunological memory without current disease. Parasite culture, although specific, is slow, technically demanding and insensitive. Together, these constraints have long argued for a shift toward methods that detect parasite nucleic acids directly, offering both higher analytical sensitivity and the ability to quantify parasite load for monitoring treatment response.

The quantitative core of the review centers on real-time quantitative PCR, or qPCR, targeting kinetoplast DNA. Kinetoplast DNA minicircles are small, circular mitochondrial DNA molecules present in thousands of copies per parasite, a feature that gives kDNA-targeted assays an enormous analytical advantage over single-copy nuclear targets. Pooling data across studies with a bivariate random-effects model, the review found that qPCR targeting kDNA achieved a pooled sensitivity of 95.8 percent, with a 95 percent confidence interval of 92.4 to 98.2 percent, and a pooled specificity of 98.8 percent, with a confidence interval of 96.7 to 99.7 percent. Summary receiver operating characteristic curves were generated using the hierarchical summary receiver operating characteristic model, following Cochrane guidance, and heterogeneity was quantified with the I² statistic. On the strength of these figures, the review positions kDNA-targeted qPCR as the reference standard among molecular approaches, albeit one whose performance comes with substantial infrastructure requirements.

That caveat matters. qPCR demands thermocycling instruments, continuous cold chains for reagents, reliable electricity, trained molecular biologists and quality assurance systems that are often absent precisely where leishmaniasis takes its greatest toll. Rural clinics in East Africa, South Asia and Latin America, where visceral and cutaneous disease overlap with poverty and weak laboratory networks, cannot routinely run quantitative real-time platforms. This is why the review devotes considerable attention to isothermal amplification technologies, which amplify nucleic acids at a constant temperature and therefore eliminate the need for expensive cycling equipment. The most mature of these is loop-mediated isothermal amplification, known as LAMP, which uses a set of four to six primers recognizing six to eight regions of the target sequence and a strand-displacing polymerase to generate amplification products that can be read visually by turbidity, fluorescence or color change.

The pooled performance of LAMP in the review was impressive: a sensitivity of 92.5 percent, with a 95 percent confidence interval of 87.1 to 96.4 percent, and a specificity of 98.9 percent, with a confidence interval of 96.2 to 99.9 percent. Yet the analysis also exposed a cautionary lesson about pooled diagnostic estimates. Heterogeneity among LAMP studies was extremely high, with an I² value of 98.3 percent, meaning that virtually all of the variability in reported accuracy reflected differences between studies rather than sampling variation within them. The review attributes much of this heterogeneity to primer mismatches for Leishmania aethiopica, a species that causes cutaneous disease in parts of East Africa and whose genetic divergence from better-studied species such as Leishmania donovani and Leishmania major can undermine primer binding. The finding underscores a recurring theme in molecular diagnostics: assay performance is not a property of the technology alone but of the fit between primers and the local parasite population.

Even faster than LAMP is recombinase polymerase amplification, or RPA, which operates at body temperature, typically 37 to 42 degrees Celsius, and can produce a result in as little as 15 to 20 minutes. RPA recruits recombinase enzymes to pair primers with their target sequence and a strand-displacing polymerase to extend them, making it uniquely tolerant of crude sample preparation and low-resource settings. In the review, RPA showed strong agreement with qPCR, with a Cohen’s kappa of 0.89, a level of concordance that supports its use as a point-of-care test. For field epidemiology, outbreak investigation and primary care in endemic villages, a test that returns an answer within a single patient visit, without a laboratory, could change the practical epidemiology of the disease, enabling same-day treatment decisions and reducing the losses to follow-up that plague current diagnostic pathways.

Another frontier highlighted by the review is the move away from invasive sampling. Traditional confirmation of visceral leishmaniasis may require splenic or bone marrow aspiration, procedures that carry real risk and require surgical skill. The review found that non-invasive samples, including urine, adhesive tape discs pressed against suspected skin lesions, and skin swabs, achieved a pooled molecular sensitivity of 93.9 percent, with a 95 percent confidence interval of 88.4 to 97.4 percent. Urine in particular has attracted interest because it can be collected repeatedly, safely and by minimally trained personnel, allowing parasite DNA detection and treatment monitoring without any needle. Tape discs and swabs open a similar door for cutaneous and mucocutaneous disease, where biopsy of facial lesions can be disfiguring. If non-invasive molecular sampling can be standardized, it would remove one of the last practical barriers to confirming diagnosis in primary care.

The review does not abandon serology entirely; instead it documents its modernization. Novel peptide-based enzyme-linked immunosorbent assays using the BT7 and EL1 peptides achieved an area under the curve of 0.971, approaching the discrimination of molecular tests while retaining the simplicity and low cost of antibody detection. Separately, a recombinant antigen derived from the Leishmania donovani Aurora kinase protein, designated LdAIRK, showed strong performance as a test of cure, addressing one of the most vexing problems in visceral leishmaniasis management: distinguishing patients who have been cured from those who will relapse or develop post-kala-azar dermal leishmaniasis. Conventional antibody tests remain positive for years after cure, making them useless for follow-up, so an antigen that tracks active infection status could transform post-treatment surveillance, particularly in South Asia where PKDL reservoirs sustain transmission.

The review is candid about what remains missing. Despite the proliferation of targeted amplification assays, next-generation sequencing has not yet been established for direct clinical diagnosis of leishmaniasis, leaving species identification, mixed infections and emerging drug resistance largely dependent on older tools such as restriction fragment length polymorphism analysis and internal transcribed spacer sequencing in reference laboratories. High-resolution melting analysis and miniature direct-on-blood PCR nucleic acid lateral flow immunoassays, abbreviated mini-dbPCR-NALFIA, appear among the innovations catalogued, but cost-effectiveness analyses, which health ministries need to justify procurement, are conspicuously absent from the literature. The review’s conclusion is therefore twofold: molecular methods have genuinely advanced, with qPCR setting the accuracy benchmark and isothermal platforms closing the accessibility gap, but heterogeneity across studies demands standardized protocols, shared primers and validated reference materials before these gains can be translated into routine practice across the 98 countries where the disease persists.

Subject of Research: Recent advances in molecular diagnosis of human leishmaniasis

Article Title: Recent advances in molecular diagnosis of human leishmaniasis

Article References: Asseri, J. I. (2026). Recent advances in molecular diagnosis of human leishmaniasis. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14357-5

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14357-5

Keywords: Recent, advances, molecular, diagnosis, human, leishmaniasis, scientific research

Naringin has been studied for decades as a pharmaceutical treasure. It belongs to the flavanone glycosides, a family of plant secondary metabolites linked in the scientific literature to anti-inflammatory, antioxidant, and metabolic benefits, and it is the dominant bitter compound in the rind and flesh of Huajuhong fruit, a traditional Chinese medicine material. The enzymes that build naringin step by step were already well characterized: phenylalanine ammonia-lyase, chalcone synthase, flavone synthase, and two glycosyltransferases that decorate the flavanone backbone with sugars. What remained murky was the regulatory layer above those enzymes, the machinery that decides when the whole pathway should be switched on in response to environmental and hormonal cues.

The research team, led by Genlin Mao, Diyang Qiu, and Ruiyi Fan from the Guangdong Academy of Agricultural Sciences and Jingchu University of Technology, focused on jasmonate, a plant hormone best known for coordinating defense responses against herbivores and pathogens. When they treated pomelo seedlings with methyl jasmonate, a cell-permeable jasmonate analog widely used as an elicitor, naringin levels surged 3.45-fold. Crucially, the gene encoding CgMYC2, a member of the basic helix-loop-helix transcription factor family, responded even faster, rising 6.6-fold before the peak expression of the five core biosynthetic genes. That timing mattered: the putative regulator switched on before its presumed targets, exactly the sequence expected of a genuine upstream controller rather than a downstream passenger.

To place CgMYC2 within the canonical jasmonate signaling cascade, the researchers turned to protein interaction assays. In the standard model of jasmonate perception, the hormone is sensed by a receptor complex that then degrades members of the JAZ family of repressor proteins. Those JAZ proteins, when present, physically clamp down on MYC transcription factors and prevent them from activating genes. Using pull-down and co-immunoprecipitation experiments, the team confirmed that CgMYC2 directly interacts with CgJAZ3, a JAZ repressor from pomelo. This interaction anchors CgMYC2 firmly in the jasmonate pathway: when jasmonate levels rise, JAZ proteins are destroyed, CgMYC2 is released, and the biosynthetic genes can be transcribed.

The next question was whether released CgMYC2 actually touches the DNA of the naringin pathway genes. The answer came from a battery of complementary techniques. Yeast one-hybrid assays confirmed binding to the promoter of Cg1,2RhaT, the rhamnosyltransferase that performs the final sugar-transfer step in naringin synthesis. Electrophoretic mobility shift assays went further, demonstrating that CgMYC2 binds directly, and in a G-box-dependent manner, to the promoters of all five core biosynthetic genes: CgPAL5, CgCHS, CgFNS, Cg7GlcT, and Cg1,2RhaT. The G-box is a short DNA motif, the canonical binding site for bHLH transcription factors, and mutating or masking it abolished the interaction, establishing the molecular grammar of the connection.

Binding alone does not prove activation, so the team ran dual-luciferase transactivation assays, a technique in which a promoter is wired to a light-producing reporter enzyme. CgMYC2 transactivated all five promoters, with the strongest effect on CgCHS, the chalcone synthase gene that catalyzes the first committed step of flavonoid biosynthesis. As chromatin-level support, a single-sample CUT&Tag profiling experiment revealed that CgMYC2-associated genomic regions were enriched for G-box motifs across jasmonate-responsive and secondary-metabolic loci, painting a genome-wide picture of the regulator in action. Together, these assays build a causal chain from hormone perception to promoter occupancy to transcriptional output.

Genetic loss-of-function evidence sealed the argument. Using virus-induced gene silencing, a technique that co-opts a plant viral mechanism to knock down endogenous gene expression, the researchers suppressed CgMYC2 in pomelo seedlings. Naringin content dropped by roughly 21 percent, and the expression of the biosynthetic genes fell in parallel. The partial rather than complete reduction suggests redundancy among MYC-family members or contributions from other regulatory pathways, but the direction and coherence of the effect confirm that CgMYC2 is a positive, load-bearing component of the naringin regulatory network.

Perhaps the most striking result came from moving the gene into a completely different species. When the team overexpressed CgMYC2 heterologously in tomato, the transgenic plants activated their own flavonoid pathway and accumulated elevated levels of sixteen different flavonoid compounds. This cross-species functionality indicates that the MYC2-to-G-box regulatory logic is evolutionarily conserved, consistent with earlier work in tomato where an SlMYC2-SlMYB12 module orchestrates fruit flavonoid metabolism, and with jasmonate-driven MYC2 regulation of anthocyanin accumulation in Arabidopsis. A regulatory principle discovered in a medicinal pomelo thus appears to be a general design feature of plant secondary metabolism.

The practical implications extend in several directions. For breeders of Huajuhong and other citrus, CgMYC2 offers a molecular marker and a potential editing target for tuning naringin content, whether the goal is maximizing medicinal quality or reducing bitterness in juice cultivars. The study also connects to a broader agricultural context: recent work has shown that stabilizing MYC2 in citrus can confer resistance to Huanglongbing, the devastating citrus greening disease, suggesting that a single regulatory node influences both defense chemistry and quality traits. More broadly, jasmonate elicitation is already used to boost secondary metabolite production in medicinal plants, and knowing the specific transcription factor that gates a target pathway makes such elicitation strategies far more predictable and engineerable.

Scientifically, the study exemplifies how modern plant biology dissects a regulatory question by triangulating across scales: hormone physiology, gene expression kinetics, protein-protein interaction, protein-DNA binding, chromatin profiling, and transgenic functional tests all converge on the same answer. CgMYC2 emerges as a bridge between jasmonate perception and naringin biosynthesis, a single point of control where an environmental signal becomes a chemical phenotype. For a compound with documented pharmacological relevance and a central role in the identity of one of China’s most valued medicinal fruits, that bridge is likely to attract intense attention from both basic researchers and the citrus industry in the years ahead.

Subject of Research: Jasmonate-regulated transcriptional control of naringin flavonoid biosynthesis in Citrus grandis 'Tomentosa'

Article Title: CgMYC2 directly activates jasmonate-induced naringin biosynthesis in Citrus grandis 'Tomentosa'

Article References: CgMYC2 directly activates jasmonate-induced naringin biosynthesis in Citrus grandis 'Tomentosa'. (n.d.). https://doi.org/10.1007/s00299-026-03960-0

Image Credits: AI Generated

DOI: 10.1007/s00299-026-03960-0

Keywords: CgMYC2, naringin, jasmonate, Citrus grandis, flavonoid biosynthesis, bHLH transcription factor, JAZ repressor, G-box, methyl jasmonate, plant hormone signaling, secondary metabolism, virus-induced gene silencing

The study’s technical innovation lies in separating two DNA modifications that standard tools cannot distinguish. The most common epigenetic mark, 5-methylcytosine, or 5mC, typically silences gene expression when it appears in promoter regions. Under the action of TET enzymes, 5mC can be oxidized into 5-hydroxymethylcytosine, or 5hmC, a demethylation intermediate that often has the opposite effect and may activate genes. Traditional bisulfite sequencing, the workhorse of DNA methylation research, converts unmethylated cytosines to uracil but leaves both 5mC and 5hmC untouched, so the resulting measurement is actually a composite of the two marks. To untangle them, the researchers ran two parallel assays on the same DNA samples: targeted bisulfite sequencing to capture the combined signal, and APOBEC-coupled epigenetic sequencing, which uses an enzyme to label hydroxymethylated cytosines with glucose so they survive deamination while methylated and unmodified cytosines are converted. Subtracting the hydroxymethylation level from the composite level yielded what the team calls true methylation.

The study population was drawn from two established Chinese cohorts. Cases came from the China Antihypertensive Trial in Ischemic Stroke, a multicenter randomized trial of blood pressure management after stroke, from which 615 patients with imaging-confirmed ischemic stroke were selected. Controls, totaling 610 individuals, were frequency-matched by age and sex from the Prevention of Metabolic Syndrome and Multi-Metabolic Disorders Study, a community-based prospective cohort. The participants averaged 62 years of age, with roughly equal numbers of men and women in each group. As expected, stroke patients carried a heavier burden of metabolic risk factors, including hypertension, diabetes, obesity, hyperglycemia, and dyslipidemia, and the two groups also differed in education level. These characteristics were carefully accounted for in the statistical models, which adjusted for age, sex, education, smoking, drinking, body mass index, blood lipids, hypertension, and diabetes.

The target region spanned nine CpG sites in the NPPA promoter, located between 540 and 276 base pairs upstream of the transcription start site on chromosome 1. Genomic DNA extracted from peripheral blood mononuclear cells was processed through both sequencing pipelines, with stringent quality control: samples showing bisulfite conversion rates below 98 percent or average sequencing coverage under 20-fold were excluded. The nine CpG sites were then analyzed individually and collectively. For the gene-level analysis, the researchers employed the weighted truncated product method, which combines P values across multiple sites while weighting each by its regression coefficient, a strategy designed to detect joint effects that individual site analyses might miss when each contributes only a small share of the overall signal.

The methylation results were striking. At eight of the nine CpG sites, true methylation levels were significantly lower in stroke patients than in controls, and this hypomethylation was negatively associated with the risk of having an ischemic stroke. These associations survived correction for multiple testing using the false discovery rate approach, with all q values below 0.05. When the nine sites were considered together, the gene-based association was significant, and the mean methylation level across the region showed a clear dose-response relationship: each unit increase in mean true methylation corresponded to an odds ratio of 0.94 for stroke, with a 95 percent confidence interval of 0.91 to 0.97. Subgroup analyses revealed that the association was more pronounced among older participants, women, non-smokers, non-drinkers, and those with lower educational attainment, findings the authors suggest could guide the clinical application of epigenetic markers.

Hydroxymethylation told a different and more nuanced story. Although median hydroxymethylation levels at the assayed sites tended to be higher in stroke patients, only one CpG site, designated CpG2 and located at chromosome 1 position 11,908,348, showed a statistically significant positive association with stroke after covariate adjustment and multiple testing correction, with an odds ratio of 1.39 and a 95 percent confidence interval of 1.15 to 1.68. The gene-based test for hydroxymethylation was also significant, indicating a joint effect across the region, but the mean hydroxymethylation level alone did not distinguish cases from controls. Notably, CpG2 was the only site where both methylation and hydroxymethylation were independently associated with stroke, making it a particularly intriguing candidate for future precision interventions if the relevant technologies mature.

Beyond stroke risk, the researchers asked whether these epigenetic marks could predict recovery. They followed 598 of the 615 stroke patients, after excluding 17 lost to follow-up, and assessed functional outcome at three months using the modified Rankin Scale, an ordinal measure ranging from no symptoms to death. In ordered logistic regression models that additionally adjusted for stroke subtype, time from onset to hospitalization, stroke severity on the National Institutes of Health Stroke Scale, and treatment assignment, true methylation levels at all eight significant CpG sites were associated with a lower risk of scoring higher on the scale, meaning better neurological recovery. A complementary binary analysis defining poor outcome as a modified Rankin Scale score of 3 or higher produced consistent results. Hydroxymethylation, by contrast, showed no significant association with functional outcome at any site, and the gene-based test for hydroxymethylation and outcome was not significant.

The findings fit into a broader scientific context. Circulating ANP levels have previously been linked to ischemic stroke and to 90-day mortality and functional outcomes after stroke onset, and genetic variants in NPPA have been associated with both ANP levels and stroke susceptibility in studies of Chinese and Korean populations. Because promoter methylation generally suppresses gene expression, the observed hypomethylation in stroke patients is consistent with reports that stroke patients carry higher serum ANP levels, though the authors caution that a direct causal link between NPPA promoter methylation and ANP expression has not yet been verified; in their own earlier work, methylation at these same sites did not significantly predict serum proANP levels. Animal studies add another layer: mice experiments have shown that 5hmC can protect the brain from ischemic injury, and knockdown of the TET enzymes that generate 5hmC worsened brain degeneration in models of focal ischemia.

The study’s implications reach toward prevention and treatment. Because epigenetic modifications are chemically reversible, unlike fixed genetic variants, the CpG sites identified here could serve not only as biomarkers for risk stratification and prognosis but also as potential therapeutic targets. This is particularly relevant given the troubled history of ANP-targeted drugs such as sacubitril/valsartan and recombinant carperitide, whose clinical use has been limited by hypotension, angioedema, and fatalities in hospital settings. A deeper understanding of how the NPPA gene is regulated at the epigenetic level might open alternative routes to modulating the ANP pathway more safely.

The authors are careful to note the limitations of their work. As an observational study, it cannot determine whether altered methylation and hydroxymethylation in the NPPA promoter are causes, consequences, or mere companions of ischemic stroke. Residual confounding cannot be fully excluded despite extensive adjustment, and the findings, derived from Chinese adults, may not generalize to other ethnic or age groups. The absence of circulating ANP measurements in the current dataset leaves the mechanistic bridge between promoter marks and hormone levels unconfirmed. Nevertheless, by simultaneously quantifying true methylation and hydroxymethylation at identical CpG sites in a large case-control sample with prospective follow-up, the study demonstrates that the two marks carry distinct information about stroke risk and recovery, and it makes a compelling case that separating them should become standard practice in epigenetic epidemiology of complex disease.

Subject of Research: Associations of NPPA promoter DNA methylation and hydroxymethylation with ischemic stroke risk and functional outcome

Article Title: Associations of NPPA promoter true methylation and hydroxymethylation with ischemic stroke and its functional outcome

Article References: Yao, J., Song, L., Jiang, J., Zhang, J., Chen, L., Fan, W., Lu, Y., Zhang, X., Jing, J., Jin, Y., Zhang, M., Hao, Y., & Peng, H. (2024). Associations of NPPA promoter true methylation and hydroxymethylation with ischemic stroke and its functional outcome. Epigenetics Communications, 4(1), Article 6. https://doi.org/10.1186/s43682-024-00029-5

Image Credits: AI Generated

DOI: 10.1186/s43682-024-00029-5

Keywords: ischemic stroke, NPPA, atrial natriuretic peptide, DNA methylation, DNA hydroxymethylation, epigenetics, bisulfite sequencing, APOBEC-coupled epigenetic sequencing, modified Rankin Scale, functional outcome, biomarkers, case-control study

The study, published in the journal Veterinary Oncology, was led by Ingrid Marie Moberg and colleagues at the Norwegian University of Life Sciences, Oslo University Hospital, and the University of Oslo. The team analyzed RNA sequencing data from 179 canine mammary tumors, drawn from a cohort of naturally occurring tumors removed from companion dogs during routine surgery. Their goal was twofold: to define molecular subgroups of canine mammary tumors without reference to histology, and then to ask whether tumors from the same dog share those molecular identities. The answer to the second question, in most cases, was no.

To classify the tumors, the researchers first reduced their high-dimensional gene expression data using principal component analysis, then applied unsupervised consensus clustering, an algorithm that groups samples based purely on expression similarity and stability across repeated resampling. This revealed five robust transcriptomic clusters. Crucially, the clusters did not map cleanly onto histological diagnosis. Each cluster contained a mixture of benign and malignant tumors, confirming that the microscopic appearance of these tumors tells only part of the story of their underlying biology.

Gene set enrichment analysis then revealed that the five clusters bear a remarkable resemblance to molecular subtypes long recognized in human breast cancer. Three of the clusters showed enrichment of hormone-related gene programs, including estrogen response, and were found to harbor the transcription factor GATA3, a classic marker of luminal breast cancer in humans. One cluster combined cell-cycle proliferation with immune and interferon signaling, evoking the aggressive basal-like or triple-negative phenotype, while a fifth cluster was defined by epithelial-mesenchymal transition, angiogenesis, and inflammatory modules, reminiscent of the claudin-low subtype. The parallel with human breast cancer taxonomy is not merely cosmetic; it strengthens the case for dogs as a comparative model in which the biology of mammary cancer can be studied in a spontaneously arising disease.

Beyond clustering, the team constructed a gene co-expression network using the hCoCena framework, identifying ten modules of genes that are expressed together and that encode distinct biological processes. One module captured hormone signaling, two captured immune and interferon responses, three reflected metabolism and proliferation through glycolysis, PI3K-AKT-mTOR signaling, oxidative phosphorylation, and MYC targets, and others traced epithelial differentiation through WNT signaling, epithelial-mesenchymal transition, cell-cycle regulation through E2F targets and the G2M checkpoint, and tumor microenvironment features such as angiogenesis. Transcription factor enrichment within the modules pointed to GATA3 as a regulator of the hormonal program and E2F1 as a driver of the proliferative module, providing candidate master switches behind the observed phenotypes.

The heart of the study, however, lies in its analysis of synchronous tumors. The researchers focused on 45 dogs that each carried exactly two tumors, yielding 90 paired samples classified as benign-benign, malignant-benign, or malignant-malignant. When they compared cluster assignments within each pair, concordance was low. Only about 45 percent of tumor pairs landed in the same transcriptomic cluster overall, with malignant-malignant pairs showing the highest agreement at 56 percent, benign-benign pairs at 44 percent, and mixed malignant-benign pairs at just 36 percent. In other words, the majority of dogs carried two tumors with fundamentally different molecular identities.

To quantify this divergence at the level of individual genes, the team calculated intraclass correlation coefficients for every gene across the paired samples. Genes were scored as low, moderate, or high in correlation between a dog’s two tumors. The results were unambiguous: between roughly 76 and 90 percent of genes showed low correlation across all diagnostic categories, and fewer than one percent of genes were highly correlated within any category. This pattern of widespread discordance held regardless of whether both tumors were benign, both malignant, or one of each, indicating that molecular independence between synchronous tumors is the norm rather than the exception.

A small set of exceptions proved informative. The analysis identified a handful of genes, including OMD and EN1, whose expression is strongly correlated within certain categories of synchronous tumor pairs and which have been reported as prognostic markers in human cancers. The authors suggest that these genes may point to shared disease processes or protective mechanisms against malignant transformation, and that they deserve further investigation, potentially at the DNA level, to uncover any genetic factors underlying their coordinated behavior. Meanwhile, examination of module-level variation showed that programs linked to cell-cycle activity, hormone signaling, and immune responses fluctuated most between paired tumors, while modules tied to epithelial differentiation and metabolism remained comparatively stable within individuals.

The clinical implications of this work reach in two directions at once. For veterinary medicine, the findings suggest that each tumor in a multi-tumor patient should be evaluated as a biologically independent lesion rather than assumed to be representative of its neighbors. Because molecular subtypes in human breast cancer drive dramatically different treatment decisions, from endocrine therapy for hormone receptor-positive disease to chemotherapy and PARP inhibitors for triple-negative tumors, a biology-driven approach could eventually refine the limited therapeutic options currently available for canine patients. The authors note, for instance, that identifying hormone-positive subtypes could inform whether ovariohysterectomy offers real benefit at the time of tumor removal, a decision veterinarians currently make without molecular guidance.

For comparative oncology, the study reinforces the value of the canine model in a way that human cohorts cannot easily replicate. Synchronous bilateral breast cancer occurs in only around one percent of human patients, whereas synchronous mammary tumors affect the majority of affected dogs. Studying these paired tumors within the same genetic background eliminates many host-specific confounders, offering a natural experiment in tumor evolution and inter-individual heterogeneity. The authors acknowledge limitations inherent to bulk RNA sequencing, which averages expression across all cells in a tissue and may reflect tissue composition as much as tumor biology, and they caution that a single RNA sample may not represent an entire tumor. Even so, their conclusion stands firm: histopathology alone does not capture the molecular reality of canine mammary tumors, and expression-based profiling offers a more faithful map of the biological terrain that clinicians and researchers alike will need to navigate.

Subject of Research: Transcriptomic heterogeneity of synchronous canine mammary tumors and their molecular resemblance to human breast cancer subtypes

Article Title: High molecular heterogeneity in synchronous canine mammary tumors detected by transcriptomic analysis

Article References: Moberg, I. M., Murphy, S. L., Hansen, N., Borge, K. S., Gunnes, G., Sørlie, T., Lingaas, F., Bergholtz, H., & Solbakken, M. H. (2026). High molecular heterogeneity in synchronous canine mammary tumors detected by transcriptomic analysis. Veterinary Oncology, 3(1), Article 11. https://doi.org/10.1186/s44356-026-00066-3

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00066-3

Keywords: canine mammary tumors, transcriptomics, RNA sequencing, tumor heterogeneity, synchronous tumors, breast cancer subtypes, gene co-expression network, consensus clustering, comparative oncology, veterinary pathology, High, molecular

The research addresses a puzzle that has long frustrated laser engineers. When a femtosecond pulse strikes a metal surface, the energy is deposited so quickly that ordinary notions of heating and melting break down entirely. The pulse duration is shorter than the time it takes for electrons to hand their energy over to the atomic lattice, meaning the material’s electrons are driven to enormous temperatures while the atoms themselves barely move at first. This state—known as two-temperature behavior—sits at the heart of why ultrashort pulses can ablate material with astonishing precision, leaving minimal heat-affected zones, recast layers, or burrs around the machined feature. Understanding exactly how the lattice then responds, and how material is ejected, requires a simulation approach that can resolve atomic motion in space and time simultaneously.

Molecular dynamics provides exactly that capability. In the study, the researchers modeled a titanium target as a vast ensemble of interacting atoms, governed by an interatomic potential calibrated to reproduce titanium’s structural, thermal, and mechanical properties. The laser pulse was incorporated through a two-temperature model, in which the absorbed optical energy first elevates the electron temperature, and energy then flows into the lattice via electron-phonon coupling. By coupling this continuum description of the electron subsystem to the atomistic dynamics of the lattice, the simulations captured the full sequence of events: from the instant of energy deposition through lattice heating, phase transformation, and the ultimate ejection of material from the irradiated zone.

One of the study’s central achievements is its systematic exploration of how the outcome depends on laser fluence—the energy delivered per unit area. At low fluences, just above the ablation threshold, the simulations reveal a delicate regime in which the near-surface region undergoes photomechanical stress confinement and fails through the generation and relaxation of intense compressive and tensile stress waves. The topmost atomic layers can be removed essentially intact, propelled outward by the release of stored thermoelastic stress, while the underlying crystal remains largely undisturbed. This gentle regime is precisely what practitioners prize for precision micromachining, because it minimizes collateral thermal damage and produces clean, well-defined surfaces.

As the fluence increases, the picture changes dramatically. The absorbed energy density climbs past the point where the lattice can remain a coherent solid, and the simulation shows the near-surface region superheating far beyond its equilibrium melting point. In this regime, the dominant material removal mechanism shifts toward explosive decomposition: the superheated, deeply undercooled liquid and even critical-point phenomena come into play, and the irradiated volume disintegrates into a mixture of vapor, clusters, and droplets. The researchers tracked the emergence of a foamy, low-density transient structure—sometimes called a subsurface bubble or cavitation zone—that expands from the center of the deposit and ultimately fragments, ejecting both atomic and nanocluster debris. These atomistic observations connect directly to experimental signatures such as the characteristic size distributions of nanoparticles collected in laser ablation plumes of titanium and other metals.

The simulations also shed light on the fate of the material left behind. Below the ablated layer, the models show rapid quenching at rates of trillions of kelvin per second, which can freeze in structural signatures quite unlike those of equilibrium titanium. Depending on depth and local energy density, the resolidified region can display amorphous character, disordered polycrystalline grains, or heavily twinned and defective crystal structures. Such subsurface defects influence surface roughness, hardness, residual stress, and even the biological response of titanium implants whose surfaces are laser-textured. By resolving these features at the atomic scale, the computational study provides a mechanistic bridge between processing parameters and the microstructure that ultimately determines device performance.

From an engineering standpoint, the value of this work lies in its ability to map the parameter space of femtosecond machining far more cheaply and comprehensively than experiment alone. Each simulation is, in effect, a virtual experiment in which fluence, pulse duration, number of pulses, and material temperature can be varied systematically, and every atom can be observed at every instant—something no microscope can achieve. The researchers analyzed how peak electron and lattice temperatures, stress profiles, and ablation depths evolve as a function of deposited energy, allowing them to identify thresholds separating stress-driven removal, phase-explosion-dominated ejection, and regimes where material is merely melted and resolidified without net removal. These thresholds correspond closely to the processing windows that laser manufacturers and job shops must navigate when optimizing titanium micromachining protocols.

The study also speaks to a long-standing debate in the ultrafast laser community about the relative importance of thermal and nonthermal mechanisms. In strongly absorbing metals excited below the threshold for nonlinear optical breakdown, the simulations support the conventional two-temperature picture: the energy deposition is thermal at the electron level, but the subsequent lattice response is so rapid and so far from equilibrium that classical thermal concepts such as boiling points lose their ordinary meaning. Instead, material removal is governed by the interplay of electron-phonon coupling strength, thermomechanical stress confinement, and the kinetics of melting and vaporization under extreme superheating. For titanium, whose electron-phonon coupling is comparatively strong, this coupling time is short enough that lattice heating begins within a few picoseconds, shaping the transition between the stress-dominated and thermally dominated ablation regimes.

The broader implications extend well beyond titanium. The methodological framework—combining a two-temperature description of laser energy deposition with large-scale molecular dynamics—is directly transferable to other transition metals, alloys, and multilayer thin films used in electronics, energy storage, and biomedical engineering. As femtosecond lasers move into high-throughput industrial settings, from drilling cooling holes in turbine blades to patterning stents and creating microtextured antibacterial surfaces, the demand for predictive process models is intensifying. Atomistic simulations of the kind reported here can feed mesoscale and continuum models, ultimately enabling digital twins of laser machining processes in which parameters are tuned in silico before a single physical part is machined.

There remain challenges on the path to fully predictive simulation. Molecular dynamics of this scale captures picoseconds of physical time, while real ablation plumes evolve over nanoseconds to microseconds, and multi-pulse processing introduces heat accumulation over far longer intervals. Experimental validation likewise demands ultrafast pump-probe diagnostics capable of watching plumes and surfaces evolve at the same temporal resolution. Nevertheless, this work marks a significant step forward in turning femtosecond laser machining from an empirically optimized craft into a quantitatively understood science. For a metal as strategically important as titanium—central to next-generation aircraft, prosthetic joints, and clean-energy hardware—knowing precisely how its atoms respond to the shortest light pulses humanity can generate is more than an academic curiosity. It is the foundation for manufacturing the components on which modern technology increasingly depends.

Subject of Research: Molecular dynamics simulation of femtosecond laser ablation of titanium

Article Title: Molecular dynamics study of femtosecond laser ablation of titanium

Article References: Parris, G., Goel, S., Nguyen, D. T., Salter, P., & Zhou, X. W. (2026). Molecular dynamics study of femtosecond laser ablation of titanium. npj Advanced Manufacturing. https://doi.org/10.1038/s44334-026-00114-8

Image Credits: AI Generated

DOI: 10.1038/s44334-026-00114-8

Keywords: femtosecond laser ablation, titanium, molecular dynamics, two-temperature model, electron-phonon coupling, phase explosion, ultrafast lasers, laser micromachining, advanced manufacturing, npj Advanced Manufacturing, Molecular, dynamics

The work comes at a moment when antibiotic resistance is widely regarded as one of the most urgent threats to global health. The World Health Organization and countless research groups have warned that the misuse and overuse of antimicrobials in human medicine, livestock production, and agriculture have accelerated the evolution of bacteria that shrug off conventional treatments. These multidrug-resistant pathogens, often dubbed superbugs, develop resistance through several adaptive mechanisms, including genetic mutation, horizontal gene transfer, enzymatic degradation of drugs, and the formation of protective biofilms that antibiotics struggle to penetrate. Traditional antibiotics are further hampered by rapid degradation in biological environments, non-specific targeting, and toxicity at higher doses, all of which reduce clinical efficacy and contribute to rising morbidity and mortality.

The research team, led by Noor Akbar and Naveed Ahmed Khan of the University of Derby along with colleagues at the International Center for Chemical and Biological Sciences at the University of Karachi, Ruqaiyyah Siddiqui, and other collaborators, approached the problem through the lens of nanomedicine. Their carrier of choice was the multi-walled carbon nanotube, a hollow cylindrical nanostructure made of concentric graphene cylinders held together by van der Waals forces. Carbon nanotubes possess exceptional electrical, mechanical, thermal, and chemical properties, and their nanometer-scale diameters combined with micron-scale lengths give them an enormous surface area for chemical reactivity. Crucially, they can penetrate cell membranes and be functionalized with bioactive molecules, which is precisely what makes them attractive as drug delivery vehicles, even though their best-known applications have historically been in composite materials, sensors, batteries, and electromagnetic shielding rather than medicine.

The synthesis process began with oxidation. The team dispersed multi-walled carbon nanotubes in a 3:1 mixture of sulfuric and nitric acids and sonicated the mixture for ten hours while keeping the temperature below 50 degrees Celsius. This harsh treatment planted oxygen-containing functional groups, chiefly carboxylic acid moieties, onto the nanotube walls, creating reactive anchoring points. The oxidized nanotubes, abbreviated OMC, were then filtered, washed to neutral pH, and dried under high vacuum. Next came the glucosamine. Using EDC and NHS as coupling agents, standard reagents for forming amide bonds in bioconjugate chemistry, the researchers covalently attached glucosamine, an amino sugar, to the carboxylic groups on the nanotube surface. The amino group of glucosamine reacts with surface carboxylic moieties to form stable amide linkages, and the resulting material, GA-OMC, was collected and dried at 50 degrees Celsius.

With the sugar-decorated nanotubes in hand, the researchers loaded them with two drugs selected for different reasons. Ethacridine lactate is a well-established topical antibacterial agent with broad-spectrum activity, but its clinical use is limited by cytotoxicity and inefficient delivery. Sulfamethoxazole is a clinically relevant systemic antibiotic that served as a test of whether the nanocarrier could enhance the efficacy of an existing therapeutic while reducing its toxicity. Drug loading was accomplished by dissolving each drug at 1 milligram per milliliter and adding the solutions dropwise to suspensions of GA-OMC, followed by 24 hours of stirring at room temperature and centrifugation at 13,000 rpm to remove unbound drug. The interactions between the drugs and the nanocarrier are predominantly non-covalent, involving electrostatic attraction, ion-dipole forces, hydrogen bonding, and pi-pi stacking between aromatic rings.

A battery of characterization techniques confirmed the success of each synthetic step. Thermogravimetric analysis, performed from room temperature to 800 degrees Celsius under nitrogen, revealed distinct weight losses corresponding to surface modifications: pristine nanotubes lost only 2.39 percent of their mass up to 450 degrees Celsius, while oxidized nanotubes lost 16.44 percent and the glucosamine-functionalized material lost a further 10.62 percent attributable to decomposition of the attached organic sugar moiety. Fourier-transform infrared spectroscopy verified the chemistry, showing a new amide carbonyl peak near 1687 inverse centimeters in the functionalized material, confirming covalent bond formation, along with shifted drug-characteristic peaks in the loaded formulations that indicate successful drug-carrier interactions. Scanning electron microscopy showed smooth sidewalls on pristine nanotubes transformed into rugged, defective surfaces after functionalization, with the tubes also becoming shorter through successive processing. Ultraviolet-visible spectroscopy delivered perhaps the most clinically important numbers: encapsulation efficiencies of 85.37 percent for ethacridine lactate and 93.69 percent for sulfamethoxazole, meaning the carrier captured the overwhelming majority of drug offered to it. Dynamic light scattering measured hydrodynamic diameters between roughly 127 and 429 nanometers, moderate polydispersity, and stable negative zeta potentials between minus 17 and minus 23 millivolts, confirming that the nanoconjugates resist aggregation in suspension.

The biological results are where the story becomes genuinely striking. The team tested the materials against seven clinically isolated, multidrug-resistant strains spanning both major bacterial classes: the Gram-negative Escherichia coli K1, Salmonella enterica, Serratia marcescens, and Pseudomonas aeruginosa, and the Gram-positive Streptococcus pneumoniae, Streptococcus pyogenes, and Bacillus cereus. In standard colony-forming assays, individual nanotubes, oxidized nanotubes, and free glucosamine showed negligible activity. But conjugation changed everything. The sulfamethoxazole-loaded nanoconjugate, SMX-GA-OMC, boosted inhibition far beyond what the free drug achieved, reaching 75.47 percent inhibition against E. coli K1, 77.58 percent against Salmonella, 89.79 percent against Serratia, and, remarkably, 100 percent against Bacillus cereus, where the free drug managed only 68.33 percent.

The ethacridine lactate conjugate, EL-GA-OMC, performed even better. Against every tested strain, it achieved complete, 100 percent bacterial eradication, matching the positive control gentamicin, while the free drug reached between 76.5 and 91.96 percent inhibition. Half-maximal inhibitory concentration analysis added quantitative rigor to these observations. Against E. coli K1, the EL-GA-OMC nanoconjugate reached 50 percent inhibition at just 10.20 micrograms per milliliter, nearly four times more potent than the free drug at 39.20 micrograms per milliliter. Against Streptococcus pneumoniae, the nanoconjugate achieved an IC50 of 10.74 micrograms per milliliter compared with 33.84 for free ethacridine lactate. The sulfamethoxazole conjugate similarly lowered its IC50 against E. coli K1 from 113.07 to 46.14 micrograms per milliliter. Statistical analysis confirmed these differences were highly significant.

Just as important as the enhanced killing was what the nanoconjugates did not do: damage human cells. Using human cerebral microvascular endothelial cells, HBEC-5i, the researchers ran lactate dehydrogenase release assays to quantify cytotoxicity after 24 hours of exposure. Free ethacridine lactate alone was clearly toxic, lysing 45.37 percent of cells. Yet when the same drug was delivered on the glucosamine-functionalized nanotubes, cytotoxicity plummeted to just 14.41 percent. The sulfamethoxazole conjugate registered 12.82 percent, and cell viability remained above roughly 80 percent for all nanoconjugates tested. This decoupling of antibacterial potency from host toxicity is precisely the property that makes a drug delivery platform clinically interesting.

The findings echo earlier reports that functionalized carbon nanotubes can serve as effective antibiotic carriers, including studies showing that levofloxacin-loaded nanotubes exhibit robust antibacterial activity with minimal toxicity, and nanotube-based systems carrying fluoxetine and isoniazid that improved outcomes against Mycobacterium tuberculosis while modulating resistance-related genes. What distinguishes the new work is the combination of a biologically familiar sugar, glucosamine, as the surface functionalization, the near-perfect encapsulation efficiencies, and the demonstration of complete eradication across multiple resistant Gram-positive and Gram-negative strains alongside documented low cytotoxicity.

The authors note that further work remains before such systems approach the clinic, including conventional MIC and MBC determinations, time-kill assays, comparisons with physical drug-nanotube mixtures, drug-release kinetics, and pharmacokinetic evaluation. Safety across the full life cycle of carbon nanomaterials also remains an active area of regulatory and toxicological scrutiny. Nevertheless, the study offers a compelling proof of principle that a simple amino-sugar grafted onto one of nanotechnology’s most iconic materials can transform two imperfect antibacterial agents into formulations that kill resistant bacteria at sharply reduced doses while sparing human cells. In a decade in which superbugs are projected to claim millions of lives annually, that combination of potency and selectivity is exactly what the field has been searching for.

Biofilms are not simply piles of bacteria stuck to a surface. They are organized communities embedded in an extracellular matrix, a protective material that can limit the penetration of disinfectants, reduce exposure to environmental stresses and help cells remain attached to equipment, food-contact surfaces or host tissues. In Salmonella Typhimurium, two major matrix components are curli fimbriae and cellulose. Curli are thin protein fibers with amyloid-like properties that help cells adhere to one another and to surfaces, while cellulose is a polysaccharide that contributes mechanical strength and affects the architecture of the growing community. CsgD is a central transcriptional regulator of these traits. When CsgD activity rises under conditions favorable to a biofilm lifestyle, it activates or coordinates genetic programs that promote matrix production and suppress aspects of a free-swimming existence.

The new study examines whether that structural role is connected to quorum sensing, a form of chemical communication in which bacteria adjust gene expression in response to signal concentrations. Salmonella participates in LuxS-dependent signaling involving autoinducer-2, or AI-2. The compound is produced through the activated methyl cycle, a metabolic pathway that links cellular chemistry to communication, and can act as a broadly shared signal in mixed microbial communities. In Salmonella, AI-2 is imported and processed through the Lsr system. LsrA forms part of the transporter that brings AI-2-related molecules into the cell, LsrK phosphorylates the imported signal, and LsrR functions as a regulator that responds to the signaling state. This arrangement allows the bacterium to connect the extracellular chemical environment with changes in transcription, behavior and community organization.

To probe the relationship between CsgD and this signaling network, the researchers altered csgD expression in Salmonella Typhimurium and measured the effects on several small regulatory RNAs. These molecules, often called sRNAs, do not usually encode proteins. Instead, they can bind messenger RNAs, recruit RNA chaperones or influence translation and RNA stability, allowing bacteria to reprogram their physiology quickly. The study focused on MicA, CsrB, CsrC and RyeE, four sRNAs implicated in regulatory pathways associated with stress responses, metabolism, biofilm development or quorum-sensing-linked behavior. Using quantitative real-time polymerase chain reaction, or qRT-PCR, the team quantified changes in RNA abundance after CsgD levels were perturbed. The analyses showed that expression of all four sRNAs increased following changes to CsgD, indicating that the biofilm regulator is connected to a broader post-transcriptional control system rather than acting only on matrix-associated genes.

That result is important because bacterial regulation is often distributed across several layers. A transcription factor such as CsgD can alter the production of messenger RNAs, but sRNAs can then fine-tune whether those messages are translated into proteins. CsrB and CsrC, for example, are associated with the Csr regulatory system, in which RNA molecules can sequester the RNA-binding protein CsrA and thereby influence metabolism, motility and biofilm formation. MicA can affect the expression of target genes through base-pairing interactions, while RyeE, also known as CyaR, has been linked to nutritional status and collective bacterial behavior. The researchers did not establish that every observed RNA change is a direct physical interaction with CsgD. Instead, the results identify coordinated shifts consistent with CsgD influencing, directly or indirectly, a regulatory network that reaches far beyond the genes encoding curli and cellulose.

The strongest signal emerged when the researchers measured AI-2 activity. Salmonella strains engineered to overexpress csgD showed a 277 percent increase in relative AI-2 activity compared with the wild-type strain. In practical terms, the measured activity was approximately 3.77 times the wild-type reference under the study conditions. This does not necessarily mean that CsgD directly produces AI-2 or that the signal is increased by exactly the same amount in every environment. Rather, it indicates that elevated CsgD changes the cellular state in a way that substantially alters the detectable AI-2 signaling output. The effect could involve AI-2 production, processing, transport, signal turnover or the balance among these processes. By linking a biofilm-state regulator to a chemical communication readout, the result suggests that the decision to form a surface-associated community may be coupled to how Salmonella senses neighboring cells and nutrient conditions.

Gene-expression measurements of the Lsr system provided a more detailed view of that connection. In the strain with elevated AI-2 activity, lsrK expression increased markedly. Because LsrK phosphorylates AI-2-related molecules after uptake, greater production of this enzyme could change the rate at which the signal is processed inside the cell and could influence feedback through the Lsr pathway. The researchers also found a contrasting pattern after csgD deletion: lsrA, lsrK and lsrR were all upregulated, while measured AI-2 activity remained largely unchanged. This apparent mismatch is biologically informative. More transcript does not automatically produce more functional signal, because transport, enzymatic processing and regulatory feedback must all remain coordinated. The authors propose that the inhibitory influence of LsrR on quorum-sensing signaling may be counterbalanced by increased expression of the transporter and kinase genes, helping to keep overall AI-2 activity relatively stable despite major changes in transcription.

The deletion experiments also reinforced CsgD’s established role in biofilm biology. Loss of csgD reduced biofilm-associated phenotypes, including curli- and cellulose-related traits and total biofilm biomass. When csgD was reintroduced in a complemented strain, these traits were partially restored. Complementation is a useful test because it helps distinguish effects caused by the targeted gene from unrelated changes that might arise during strain construction. The partial, rather than necessarily complete, restoration may reflect differences in gene dosage, regulatory context or the precise physiological state of the engineered cells. Together, the phenotype data and gene-expression results support a model in which CsgD integrates the construction of the extracellular matrix with signaling pathways that help bacteria coordinate group behavior. The work does not show that quorum sensing alone determines whether a Salmonella biofilm forms, but it does indicate that the two systems are functionally entangled.

That entanglement could matter in real-world settings where Salmonella encounters diverse microbial communities. Food-processing facilities, soil, animal production systems and the intestinal tract contain mixtures of organisms that release metabolites and signaling molecules. AI-2 is particularly relevant in such environments because it is produced by many bacteria, making it less like a private password and more like a shared chemical indicator of microbial activity. A Salmonella cell that simultaneously detects conditions favorable for matrix production and elevated community signaling may adopt a more persistent lifestyle. Conversely, disrupting the regulatory links between CsgD, sRNAs and the Lsr system might weaken biofilm formation or make established communities more vulnerable to cleaning measures. The present study does not test a treatment, disinfectant or therapeutic compound, and it does not demonstrate that targeting CsgD would be safe or effective in animals or humans. Its significance is mechanistic: it maps a possible control point that could be investigated in future intervention studies.

The findings also add nuance to the idea of bacterial “conversation.” Quorum sensing is often described as a simple population-density switch, but AI-2 activity depends on metabolism, transport and feedback, while biofilm development depends on stress, nutrient availability, second messengers such as cyclic-di-GMP and multiple RNA regulators. CsgD appears to participate in this layered decision-making process, helping Salmonella balance movement, attachment, matrix production and communication. The authors emphasize that some links in their proposed network, particularly the connections between CsgD and curli or cellulose, were established by previous research, whereas the CsgD–sRNA–AI-2/Lsr relationships were investigated in the new work. Further experiments will be needed to determine which connections are direct, how they change across temperatures and nutrient conditions, and whether the same regulatory architecture operates in clinical isolates or mixed-species biofilms. Even so, the study offers a compelling explanation for how a pathogen can turn a genetic biofilm program into a coordinated community response—and why a microscopic regulatory shift may have consequences for the persistence of contamination.

Subject of Research: The regulatory links between CsgD, small regulatory RNAs, AI-2 quorum sensing and biofilm formation in Salmonella Typhimurium

Article Title: The regulatory network of Salmonella biofilm formation: the role of CsgD on autoinducer-2 activity and expression of quorum-sensing-related genes in Salmonella Typhimurium

Article References: Aşan, M., Özdemir, F.N. & Akçelik, N. Molecular Genetics and Genomics 301, 175 (2026). Original research article

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02508-x

Keywords: Salmonella Typhimurium, CsgD, biofilm formation, autoinducer-2, quorum sensing, small regulatory RNAs, Lsr system, curli, cellulose

Stromal cells include fibroblasts and related connective-tissue populations that provide structural support, regulate extracellular matrix composition and communicate with epithelial and immune cells. In healthy organs, these cells contribute to tissue repair, maintain local architecture and help coordinate the movement and survival of leukocytes. During Crohn’s disease, however, stromal cells can adopt disease-associated states. They may produce chemokines that attract immune cells, growth factors that influence their survival and matrix proteins that remodel the tissue. The new work focuses on the molecular layer that allows these states to emerge: epigenetic regulation, a system of chemical and structural changes that controls gene activity without altering the underlying DNA sequence.

Epigenetic regulation includes DNA methylation, modifications to histone proteins and changes in the three-dimensional organization of chromatin. Together, these mechanisms determine whether particular genes are accessible to the transcriptional machinery. A stromal cell exposed to inflammatory cytokines, microbial products or signals from damaged epithelium can therefore alter its functional identity without acquiring a new genome. Some of these changes may be transient, while others can persist, creating a form of cellular memory. The study’s central implication is that inflammatory tissue conditions can impose durable regulatory programs on stromal cells, locking them into states that continue to sustain disease.

This concept helps refine the traditional view of Crohn’s disease as a direct contest between immune cells and intestinal microbes. The intestine is organized into highly specialized compartments, and immune activity depends heavily on where cells are located and which signals they encounter. Stromal populations beneath the epithelium, around blood vessels and within deeper connective-tissue layers can establish distinct molecular environments. By changing the chemokines, adhesion molecules and matrix components they produce, these cells influence which immune populations enter a region, how long they remain there and what functions they perform. A pathological niche can thus become self-reinforcing: inflammation changes stromal cells, and altered stromal cells help preserve inflammation.

The researchers’ analysis distinguishes stromal cell states rather than treating fibroblasts as a single uniform population. This is technically important because tissues contain multiple stromal subsets with different developmental origins, anatomical locations and gene-expression programs. Modern single-cell and chromatin-based approaches can separate these populations by measuring RNA transcripts alongside regulatory features that indicate which parts of the genome are active or poised for activation. Such analyses can reveal disease-associated cellular states that would be invisible in bulk tissue, where signals from many cell types are averaged together. In Crohn’s disease, this resolution is particularly valuable because inflamed and relatively preserved areas may coexist within the same intestine.

The epigenetic findings also offer a possible explanation for the persistence and spatial organization of intestinal lesions. When regulatory elements controlling inflammatory genes become more accessible, stromal cells may respond more strongly to incoming cytokines. Conversely, silencing of tissue-maintenance or repair programs could reduce the ability of the intestinal wall to return to a healthy state. These changes may be reinforced by feedback between stromal cells, macrophages, T cells, endothelial cells and epithelial cells. Stromal cells can recruit and position immune cells, while immune-derived mediators can further alter stromal chromatin. The result is a multicellular circuit in which inflammation is maintained not only by immune activation, but also by the continued operation of a tissue-level regulatory program.

The work has implications for how scientists think about treatment resistance and relapse. Many current therapies for Crohn’s disease target soluble inflammatory mediators or immune-cell functions, including cytokine pathways and lymphocyte trafficking. These treatments can be highly effective, but patients may respond incompletely, lose response over time or relapse after treatment. If stromal cells retain epigenetically encoded disease programs, suppressing one inflammatory signal may not be sufficient to dismantle the niche that supports the disease. A future therapeutic strategy could therefore combine immune-directed treatment with approaches that interrupt stromal activation, alter pathogenic chromatin states or block the signals that stabilize them.

Such an approach would require considerable precision. Stromal cells are essential for normal wound healing, barrier maintenance and tissue organization, so broadly suppressing their activity could impair repair or produce unwanted fibrosis. The challenge will be to identify regulatory elements and cellular states that are specific to pathological intestinal niches rather than targeting all fibroblast functions. The study’s emphasis on epigenetic modulation may help meet that challenge by pointing toward disease-selective regulatory circuits. It may also support the development of biomarkers based on stromal gene-expression or chromatin signatures, potentially allowing clinicians to distinguish patients whose disease is driven by particular tissue programs.

The findings place Crohn’s disease within a wider movement in biology that views chronic inflammation as an ecosystem rather than a single abnormal pathway. In this model, immune cells, structural cells, blood vessels, epithelial surfaces and microbial communities interact continuously, with each component reshaping the conditions experienced by the others. Stromal cells occupy a strategic position in that network because they provide both physical scaffolding and molecular instructions. By showing that epigenetic changes can underpin distinct stromal states, the study identifies a mechanism through which local intestinal environments may become persistently pathogenic. The next step will be to determine how stable these states are in patients, whether they can be reversed safely and whether targeting them can improve outcomes beyond what immune suppression alone achieves.

Subject of Research: Epigenetic regulation of stromal cell states and pathological tissue niches in Crohn’s disease.

Article Title: Epigenetic modulation of stromal cell states underpins pathological tissue niches in Crohn’s disease.

Article References: Koplev, S., Sharma, O., Woelfel, S. et al. “Epigenetic modulation of stromal cell states underpins pathological tissue niches in Crohn’s disease.” Nature Immunology (2026). https://doi.org/10.1038/s41590-026-02617-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41590-026-02617-0

Keywords: Crohn’s disease, inflammatory bowel disease, stromal cells, fibroblasts, epigenetics, chromatin, tissue niches, intestinal inflammation, immune regulation, precision medicine

To resolve the species gap, researchers compared mice and non-human primates and used CRISPR/Cas9-based gene editing to reduce MANF in vivo and in primary cell cultures. By combining molecular assays, transcriptome profiling, and functional rescue experiments, the study mapped how acute MANF depletion reshapes survival signaling in astrocytes.

The central result is striking: MANF loss compromises astrocyte viability in monkeys but does not measurably affect astrocyte or neuron survival in mice. This divergence aligns with the broader observation that MANF knockout mice often show limited neurological phenotypes, whereas humans carrying MANF deletions develop profound developmental abnormalities. Together, the data support a primate-specific requirement for MANF in maintaining astrocyte integrity.

Mechanistically, the team identified a downstream signaling route mediated by leukemia inhibitory factor (LIF) and signal transducer and activator of transcription 3 (STAT3). Reduced MANF in monkey astrocytes leads to decreased LIF expression, which in turn dampens STAT3 pathway activity—creating pro-apoptotic conditions that trigger selective astrocyte death.

In contrast to mice, where this survival coupling is absent or functionally muted, primate astrocytes appear to rely on the MANF–LIF–STAT3 axis as a critical guardian signal. The study further demonstrates causality by showing that restoring LIF signaling can mitigate the apoptotic cascade initiated by MANF deficiency.

These findings position LIF as a plausible therapeutic leverage point for MANF-related neurodevelopmental disorders. More broadly, the work highlights the value of non-human primate models when studying human-relevant brain mechanisms that may not translate cleanly from rodents.

The research, titled “MANF is essential for astrocyte survival in the monkey brain,” was published in Protein & Cell. By clarifying how a conserved neurotrophic factor can operate through species-specific circuitry, the study provides a testable framework for targeted interventions aimed at preserving astrocyte survival during development.

Subject of Research: Experimental study
Article Title: MANF is essential for astrocyte survival in the monkey brain
Web References: http://dx.doi.org/10.1093/procel/pwag031
References: 10.1093/procel/pwag031
Image Credits: HIGHER EDUCATION PRESS
Keywords: astrocytes; MANF; LIF; STAT3; microcephaly; CRISPR/Cas9; primate neuroscience; neurotrophic signaling

TRAIL-R2 functions as a crucial mediator of apoptosis, the programmed cell death pathway that eliminates aberrant or potentially malignant cells to preserve tissue integrity. Despite the receptor’s well-established involvement in apoptotic pathways, its precise regulation in breast cancer, especially at the epigenetic level, has remained ambiguous until now. The new study delves into this by investigating how epigenetic changes, specifically promoter hypermethylation, contribute to the silencing of TRAIL-R2, thereby impacting tumor progression and patient outcomes.

The research team conducted an exhaustive analysis involving matched tumor and adjacent normal breast tissue samples from 67 breast cancer patients. Employing sophisticated techniques such as methylation-specific polymerase chain reaction (MSP), quantitative real-time PCR, and western blot assays, they demonstrated that a substantial proportion of breast tumors display hypermethylation of the TRAIL-R2 promoter region. This epigenetic modification effectively represses gene transcription, culminating in markedly reduced mRNA and protein levels within cancerous tissues compared to noncancerous counterparts.

Intriguingly, the study highlighted that promoter hypermethylation and consequent silencing of TRAIL-R2 predominantly occur in the invasive ductal carcinoma subtype, the most prevalent form of breast cancer. Additionally, an association between TRAIL-R2 silencing and patient history of oral contraceptive use was observed, suggesting potential environmental or hormonal influences on epigenetic regulation. Such findings underscore the multifactorial nature of cancer epigenetics and the importance of integrating clinical patient history into molecular investigations.

Further correlations between TRAIL-R2 expression and tumor aggressiveness were elucidated. Tumors exhibiting lower TRAIL-R2 levels tended to present with advanced pathological stages and other indicators of aggressive disease phenotype. These data reinforce the conceptual framework where loss of apoptotic signaling, driven by epigenetic repression of death receptors like TRAIL-R2, facilitates tumor cell survival, proliferation, and metastasis. The inverse relationship between promoter methylation status and receptor expression strengthens the premise that epigenetic silencing is a driving mechanism rather than an incidental finding.

Of considerable clinical interest is the association between diminished TRAIL-R2 protein expression and postmenopausal status. Menopause, characterized by significant hormonal shifts, may influence epigenetic landscapes, thereby modulating gene expression patterns critical to cancer progression. Although further studies are warranted, this observation provides a glimpse into the complex interplay between hormonal milieu and cancer epigenetics.

Moreover, preliminary survival analyses suggested that higher TRAIL-R2 expression correlates with improved overall survival among breast cancer patients. While these findings need validation in larger cohorts, they hint at TRAIL-R2’s potential utility as a prognostic biomarker, aiding in stratifying patients according to risk profiles and guiding personalized treatment decisions. The establishment of such biomarkers is imperative for advancing precision oncology.

The therapeutic implications of these discoveries are profound. Epigenetic modifications, unlike genetic mutations, present reversible targets for intervention. Agents capable of demethylating DNA or modulating chromatin states could restore TRAIL-R2 expression, reactivating apoptotic pathways dormant in tumor cells. Consequently, therapies designed to reverse epigenetic silencing might sensitize tumors to apoptosis-inducing agents, enhancing therapeutic efficacy and overcoming resistance.

This study not only enriches our understanding of TRAIL-R2’s role in breast cancer but also amplifies the broader significance of epigenetic mechanisms in oncogenesis. Epigenetic silencing of tumor suppressor genes represents a subtle yet potent means by which cancer cells evade cell death and sustain malignancy. Targeting these regulatory layers holds immense promise for future cancer therapeutics.

In conclusion, Khursheed et al. have unveiled critical insights into how TRAIL-R2 is epigenetically silenced in breast cancer, particularly via promoter hypermethylation, leading to reduced apoptotic signaling and associations with more aggressive clinicopathological features. Their work paves the way for utilizing TRAIL-R2 as a biomarker and therapeutic target, emphasizing the burgeoning role of epigenetics in cancer biology and treatment strategies.

This research not only advances the molecular understanding of breast cancer but also opens new frontiers for clinical translation, potentially improving patient prognostication and broadening therapeutic horizons. As the field moves forward, integrating epigenetic therapies alongside conventional treatments may herald a new era in combatting breast cancer’s most intractable forms.

Subject of Research: Human tissue samples

Article Title: TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer

News Publication Date: June 9, 2026

Web References: https://doi.org/10.18632/oncotarget.28891

Image Credits: Copyright © 2026 Khursheed et al. Distributed under Creative Commons Attribution License (CC BY 4.0)

Keywords: TRAIL-R2/DR5, promoter methylation, breast cancer biomarkers, tumor suppressor gene, apoptotic signaling pathways